Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479980 | 0.92 | LMNA (0.41) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4391029 | 0.92 | LMNA (0.43) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL3820204 | 0.87 | LMNA (0.59) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3296598 | 0.87 | LMNA (0.35) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL3980213 | 0.85 | KDM4E (0.55) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3815630 | 0.85 | HPGD (0.48) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL5469836 | 0.84 | LMNA (0.49) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3982424 | 0.82 | LMNA (0.48) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3288208 | 0.81 | LMNA (0.33) | LMNAHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3819899 | 0.80 | LMNA (0.45) | LMNAHPGDKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628990-B1 | NOVEL 14 AND 15 MEMBERED RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | GLAXO GROUP LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070141276-A1 | Novel 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1628988-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-10-04 | — | — | EP | disclosed |
| EP-1628988-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1625137-A1 | MACROLIDES SUBSTITUTED AT THE 4''-POSITION | GLAXO GROUP LIMITED (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101585-A1 | MACROLIDES SUBSTITUDED AT THE 4'-POSITION | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101586-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | LMNA 2615/4885HPGD 1267/4885KDM4E 3840/4885 |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | IL4, CYP51A1, IL17A | LMNA 2144/4885HPGD 2689/4885KDM4E 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.